Evidence map›Paper›PMID 39981812›Full record

ArticleJournal of cellular and molecular medicine2025

A Machine Learning Approach to Build and Evaluate a Molecular Prognostic Model for Endometrial Cancer Based on Tumour Microenvironment.

Di Wu, Zhifeng Yan, Mingxia Li, Mingyang Wang, Yuanguang Meng

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Di WuSchool of Medicine, Nankai University, Tianjin, China.ORCID 0009-0008-8460-7518
Zhifeng YanDepartment of Obstetrics and Gynecology, The First Affiliated Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Mingxia LiDepartment of Obstetrics and Gynecology, The First Affiliated Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Mingyang WangDepartment of Obstetrics and Gynecology, The First Affiliated Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Yuanguang MengSchool of Medicine, Nankai University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) incidence and the associated tumour burden have increased globally. To build a molecular expression prognostic model based on the tumour microenvironment to guide personalised treatment using a machine learning approach. Two datasets were reviewed, including a training cohort (n = 698) and a testing cohort (n = 151). All patients underwent hysterectomy ± adnexectomy ± lymph nodes dissection between December 2014 and June 2020 at the PLA General Hospital First Medical Center and received necessary and regular follow-up. We developed novel models using R software to predict factors that affect survival, such as progression-free survival and overall survival. Then, the model was optimised by evaluating the prediction efficiency in multiple dimensions. Eight hundred and forty-nine patients with EC were included in the study. Survival-related influences on EC patients were identified by univariate analysis and cox regression equations. In addition, a nomogram was visualised in conjunction with demographic characteristics and the above meaningful clinicopathological variables. Ultimately, through a comprehensive assessment, a random forest model (RF16) was developed for complementing the findings of the molecular classification of EC. The RF16 not only specifically characterises tumour molecules, but also enhances the generalizability of the model by replacing gene sequencing with immunohistochemistry. This study showed that the machine learning model (RF16) is low-cost, efficient, and clinically valuable in guiding treatment for EC patients.

Indexed as

Biomarkers, TumorCarcinoma, EndometrioidEndometrial NeoplasmsMachine LearningNomogramsAdultAgedAged, 80 and overChinaFemaleHumansMiddle AgedRandom ForestRetrospective StudiesTumor MicroenvironmentBiomarkers, Tumorendometrial carcinomaimmunohistochemistrymachine learningmolecularprognosistumour microenvironment

Identifiers

PMID39981812
PMCPMC11843467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.